Articles

Platinum Priority – Sexual Medicine
Editorial by François Alexandre Giuliano on pp. 744–745 of this issue

A Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of the Tramadol Orally Disintegrating Tablet for the Treatment of Premature Ejaculation Within Less Than 2 Minutes

By: David Bar-Ora b c lowast , Kristin M. Salottoloa b c, Alessandro Orlandoa b and James V. Winklerc for the Tramadol ODT Study Group1.

European Urology, Volume 61 Issue 1, April 2012, Pages 736-743

Published online: 01 April 2012

Keywords: Premature ejaculation, Randomized controlled trial, Placebo, Intravaginal ejaculation latency time, Premature ejaculation profile questionnaire, Tramadol

Abstract Full Text Full Text PDF (763 KB)

Abstract

Background

Premature ejaculation (PE) is a widely observed male sexual dysfunction with a major impact on quality of life for many men and their sexual partners.

Objective

To assess the safety of tramadol orally disintegrating tablet (ODT) (Zertane) and its efficacy in prolonging intravaginal ejaculation latency time (IELT) and improving Premature Ejaculation Profile (PEP) scores.

Design, setting, and participants

We conducted an integrated analysis of two identical 12-wk randomized double-blind, placebo-controlled phase 3 trials across 62 sites in Europe. Healthy men 18–65 yr of age with a history of lifelong PE according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, and an IELT ≤120s were included. There were 604 intent-to-treat subjects included in the analysis.

Intervention

Subjects were randomized to receive 1:1:1 placebo (n=200), 62mg tramadol ODT (n=206), or 89mg tramadol ODT (n=198).

Measurements

We measured overall change and fold increase in median IELT and the mean change in all four measures of the PEP. Differences across treatment groups were analyzed using Wilcoxon rank-sum tests, analysis of variance, and chi-square analyses.

Results and limitations

Tramadol ODT resulted in significant increases in median IELT compared with placebo; increases were 0.6min (1.6 fold), 1.2min (2.4 fold), and 1.5min (2.5 fold) for placebo, 62mg tramadol ODT, and 89mg tramadol ODT, respectively (p<0.001 for all comparisons). Men saw significantly greater improvement in all four measures of the PEP in both doses compared with placebo (p<0.05 for all comparisons). Tramadol ODT was well tolerated; study discontinuation occurred in 0%, 1.0%, and 1.6% of subjects in placebo, 62mg, and 89mg tramadol ODT groups, respectively. Limitations include study inclusion for men with IELT up to 120s.

Conclusions

On-demand 62mg tramadol ODT is an effective treatment for PE in a low and safe therapeutic dose and provides a new option for managing mild to severe PE.

Trial registration

ClinicalTrials.gov identifiers NCT00983151 and NCT00983736; http://clinicaltrials.gov/.

Take Home Message

Premature ejaculation (PE) has a major impact on the quality of life for many men and their sexual partners. The on-demand tramadol orally disintegrating tablet (Zertane) is a very safe and effective treatment that provides a new option for managing mild to severe PE.

Keywords: Premature ejaculation, Randomized controlled trial, Placebo, Intravaginal ejaculation latency time, Premature ejaculation profile questionnaire, Tramadol.

Footnotes

a Trauma Research Department, Swedish Medical Center, Englewood, CO, USA

b Trauma Research Department, St. Anthony Hospital, Lakewood, CO, USA

c Ampio Pharmaceuticals, Inc., Greenwood Village, CO, USA

lowast Corresponding author. Trauma Research Department, Swedish Medical Center, 501 E. Hampden Ave., Room 4-454, Englewood, CO 80113, USA.

1 Tramadol ODT Study Group: David Bar-Or, Kristin Salottolo, Alessandro Orlando, James Winkler, Kendle International Inc.

Place a comment

Your comment *

max length: 5000